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Granzyme A (GzmA) triggers cell death with apoptotic
features by targeting the endoplasmic reticulum-
associated SET complex, which contains the GzmA-
activated DNase NM23-H1, its inhibitor SET, and
Ape1. The SET complex was postulated to translocate
to the nucleus in response to oxidative stress and
participate in its repair. Because mitochondrial dam-
age is important in apoptosis, we investigated whether
GzmA damages mitochondria. GzmA induces a rapid
increase in reactive oxygen species and mitochondrial
transmembrane potential loss, but does not cleave
bid or cause apoptogenic factor release. The mito-
chondrial effect is direct, does not require cytosol,
and is insensitive to bcl-2 and caspase inhibition. SET
complex nuclear translocation, which occurs within
minutes of peroxide or GzmA treatment, is dependent
on superoxide generation since superoxide scaven-
gers block it. Superoxide scavengers also block apo-
ptosis by CTLs expressing GzmA and/or GzmB.
Therefore, mitochondrial damage is an essential first
step in killer cell granule-mediated pathways of apo-
ptosis.
Introduction
Granzyme A (GzmA), an abundant serine protease in
cytotoxic T lymphocyte (CTL) and NK cell granules, in-
duces a cell death pathway that is caspase indepen-
dent, but has many features of apoptosis (Beresford
et al., 1999; Lieberman and Fan, 2003). Targeted cells
display all the morphological features of apoptosis, but
bcl-2 overexpression or caspase inhibition do not block
the pathway, and DNA damage occurs via single-
stranded nicks, instead of by oligonucleosomal double-
stranded breaks (Beresford et al., 1999; Fan et al.,
2003a). Most of the intracellular GzmA targets identified
so far (SET [Beresford et al., 1997], HMG-2 [Fan et al.,
2002], Ape1 [Fan et al., 2003b], core and linker histones
[Zhang et al., 2001b], lamins [Zhang et al., 2001a]) are
not targeted during caspase-dependent apoptosis.
A special target of GzmA is a 270–420 kDa endoplas-
mic reticulum (ER)-associated complex, termed the
SET complex, which contains the GzmA-activated
DNase NM23-H1, the protein phosphatase PP2A inhibi-
tor pp32, and three GzmA substrates—the nucleosome
assembly protein SET, the base excision repair enzyme
Ape1, and the DNA bending protein HMG-2 (Beresford
et al., 2001). The SET complex translocates to the nu-*Correspondence: lieberman@cbr.med.harvard.educleus of target cells within minutes of GzmA loading
or CTL attack (Fan et al., 2003a). Although the normal
function of the SET complex is not known, its constitu-
ent proteins have been highly implicated in tumorigene-
sis. They have been linked to diverse functions, includ-
ing chromatin modification, transcriptional activation of
protooncogenes, DNA repair, and mRNA stability (Bren-
nan et al., 2000; Demple et al., 1991; Ma et al., 2002;
Seo et al., 2001; Shikama et al., 2000). We postulated,
based on the properties of its known components, that
the SET complex participates in the oxidative stress re-
sponse by moving to the nucleus, where it activates
expression of key early response genes and repairs oxi-
dative DNA damage (Fan et al., 2003b).
Mitochondrial damage is a key initial step in cas-
pase-dependent apoptosis, including that induced by
GzmB, in which it is triggered by proteolytic cleavage
of bid (Alimonti et al., 2001; Barry et al., 2000; Gross et
al., 1999; Heibein et al., 2000; Li et al., 1998; Luo et al.,
1998; Marchetti et al., 1996; Sutton et al., 2000). During
caspase-induced apoptosis, mitochondrial function is
completely disrupted, as evidenced by a loss of the
mitochondrial transmembrane potential (ψ) and an
increase in reactive oxygen species (ROS). Moreover,
the outer mitochondrial membrane is disrupted, leading
to the release of apoptogenic factors, including cyto-
chrome c (Kluck et al., 1997; Krippner et al., 1996; Yang
et al., 1997), HtrA2/Omi (Hegde et al., 2002; Martins et
al., 2002; van Loo et al., 2002; Verhagen et al., 2002),
endonuclease G (endoG) (Parrish et al., 2001; van Loo
et al., 2001), Smac/Diablo (Du et al., 2000; Verhagen et
al., 2000), and apoptosis inducing factor (AIF) (Susin et
al., 1999), from the intermembrane space. Some fea-
tures of mitochondrial damage can also be induced in-
dependently of the caspases by both GzmB and GzmC
(Heibein et al., 1999; Johnson et al., 2003; MacDonald
et al., 1999; Thomas et al., 2001).
In this study, we looked at the mitochondrial effects
of GzmA. We find that although GzmA does not cleave
bid or disrupt the mitochondrial outer membrane
(MOM) to cause release of the caspase pathway apo-
ptogenic factors, it directly causes a rapid increase in
ROS and loss of ψ in a caspase-independent manner
that is not blocked by bcl-2 overexpression or by cas-
pase inhibitors. Moreover, mitochondrial damage is key
to SET complex nuclear translocation and GzmA induc-
tion of apoptosis. Peroxide treatment causes some of
the SET complex to move rapidly into the nucleus.
When cells are treated with superoxide scavengers, the
SET complex does not translocate, and target cells are
protected from GzmA-mediated cell death. Moreover,
the same superoxide scavengers also block cell death
induced by CTLs expressing GzmB.
Results
GzmA Directly Induces a Rapid and Sustained
Increase in Intracellular ROS and Loss of 
During target cell attack by CTLs and NK cells, gran-
zymes are delivered into the target cell cytosol by
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356Figure 1. GzmA Induces a Rapid Increase in Intracellular ROS and Mitochondrial Transmembrane Potential Loss without MOM Rupture
(A) GzmA loading of K562 cells with PFN induces a dose-dependent increase of ROS. Cells, preloaded with HE, were analyzed by flow
cytometry 1 hr after incubation in buffer alone or buffer with H2O2 (positive control), a sublytic concentration of PFN, GzmA alone, or PFN
plus GzmA at indicated concentrations. The numbers indicate the percentage of fluorescent cells.
(B) GzmA treatment of K562 cells induces a dose-dependent loss of ψ. Cells stained with the potentiometric dye JC-1 were treated overnight
with 0.1 M staurosporine (stauro, positive control), or for 1 hr with PFN and/or GzmA as in (A). The numbers indicate the percentage of cells
in the upper-right quadrant with intact ψ and those in the lower-right quadrant with loss of ψ.
(C) The increase in ROS after GzmA loading of K562 cells with PFN occurs rapidly. Cells were treated for the times indicated and stained
for ROS.
(D) GzmA triggers an increase in ROS directly on isolated mitochondria. Mouse liver mitochondria were treated with GzmA or GzmB in the
presence or absence of cytosolic S100 fraction. Addition of cytosol did not affect ROS generation by GzmA or GzmB.
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357purified mouse liver mitochondria in the presence and press only GzmA at high levels (Heusel et al., 1994; Pham
(E) GzmA does not cleave bid when delivered by PFN into K562 cells. GzmB serves as a positive control for bid cleavage.
(F) GzmA, unlike GzmB, does not induce MOM rupture, as monitored by apoptogenic factor release. Isolated mitochondria were treated for
30 min with GzmA, catalytically inactive S-AGzmA, or GzmB in the presence or absence of cytosol (S100). Immunoblots of the mitochondrial
pellet (P) and reaction supernatants (S) were probed with antibodies to cytochrome c (Cyt c), the serine protease HtrA2, endonuclease G
(Endo G), and apoptosis inhibitory factor (AIF). Cytosolic β-actin and the mitochondrial internal protein cytochrome c oxidase IV (Cox IV)
serve as fractionation controls. These data are representative of three independent experiments.perforin (PFN). To assess the effects of GzmA on mito-
chondrial function, K562 cells were treated with recom-
binant GzmA plus native purified PFN and were ana-
lyzed by flow cytometry for changes in ROS and ψ.
GzmA loading by PFN induced a dose-dependent ac-
cumulation of intracellular ROS, as measured by detec-
tion of the conversion of hydroethidine (HE) to fluores-
cent ethidium (Figure 1A). Treated cells also exhibited a
dose-dependent decrease in ψ, assayed by the change
in fluorescence of the membrane potential-sensitive
dye 5,5#,6,6#-tetrachloro-1,1#,3,3#-tetraethylbenzimida-
zolylcarbocyanine (JC-1) (Figure 1B). Similar results
were found by staining with the dye 3,3# dihexyloxacar-
bocyanine iodide (DiOC6) (data not shown). ROS accu-
mulation and loss of ψ required GzmA delivery by
PFN, as treating cells with either GzmA or PFN alone
had little effect. Both changes required enzymatically
active GzmA, since PFN-mediated delivery of the in-
active enzyme produced by mutating the active site
Ser184 to Ala (S-AGzmA) did not alter ROS or ψ (data
not shown). GzmA increases intracellular ROS very
rapidly (within 5 min), and the increase is maintained
for at least 2 hr (Figure 1C and data not shown). The
total pool of accumulated ROS increases over time, as
seen by the increase in mean fluorescence intensity
(MFI) of the ROS indicator dye between 20 min (MFI,
12), 1 hr (MFI, 30), and 2 hr (MFI, 52). Similar results
and kinetics were obtained by using Jurkat cells (data
not shown).
GzmB induces mitochondrial damage by two distinct
pathways. One pathway, whose molecular basis is un-
known, involves direct action on mitochondria to in-
duce increased ROS and loss of ψ, but not release of
cytochrome c and other intermembrane proapoptotic
factors (Heibein et al., 1999; MacDonald et al., 1999;
Thomas et al., 2001). The other requires cleavage and
activation of cytosolic bid at a site distinct from cas-
pase-8, leading to release of proapototic factors in ad-
dition to increased ROS and loss of ψ (Alimonti et al.,
2001; Barry et al., 2000; Gross et al., 1999; Heibein et
al., 2000; Li et al., 1998; Luo et al., 1998; Marchetti et
al., 1996; Sutton et al., 2000). These two pathways can
be distinguished by treating isolated mitochondria with
GzmB in the presence or absence of cytosolic S100
fraction as a source of bid. We confirmed these results
for GzmB (Figures 1D and 1E and data not shown). De-
spite the well-documented role of bid in activating
apoptotic mitochondrial damage, we confirmed the
previous finding (Alimonti et al., 2001) that the extent of
ROS generation and ψ loss was not augmented by
adding cytosol as a source of bid. This suggests that both
bid-dependent and -independent GzmB mitochondrial
pathways independently disrupt mitochondrial electron
transport. We also looked at the effect of GzmA on freshlyabsence of cytosol. GzmA directly induced increased
ROS and loss of ψ (Figure 1D, data not shown). Add-
ing S100 cytoplasmic fraction did not reproducibly
increase the rate or magnitude of ROS induction or alter
the loss of ψ. Therefore, GzmA directly causes mito-
chondrial disruption without requiring cytosolic factors.
Moreover, the mitochondrial effect of recombinant hu-
man GzmA is not cell type or species specific since it
occurs in human K562 and Jurkat cells as well as in
mouse liver mitochondria. Similar results were obtained
when ROS production and loss of ψ were monitored
with 2#,7#-diclorofluorescein diacetate (DCFDA) and
DiOC6, respectively (data not shown).
GzmA Does Not Cleave Bid or Trigger Release
of Mitochondrial Proapoptotic Molecules
Truncated bid, produced by caspase or GzmB cleav-
age, causes mitochondrial proapoptotic factor release.
However, GzmA does not cleave bid in cytosolic ex-
tracts (data not shown), and loading cells with GzmA
and PFN does not lead to bid cleavage, while loading
with GzmB and PFN does (Figure 1E). Moreover, GzmA
does not appear to disrupt the ability of the MOM to
contain intermembrane proteins. Treatment of purified
mitochondria with GzmA in the presence or absence of
S100 cytoplasmic fraction does not trigger the release
of apoptogenic factors from the mitochondrial inter-
membrane space (Figure 1F). As expected, the catalyti-
cally inactive S-AGzmA also does not cause mito-
chondrial proteins to be released. This is in contrast
to GzmB treatment, in which all four of the five known
intermembrane apoptogenic factors studied (cyto-
chrome c, HtrA2/Omi, endoG, and AIF) were detected
in the supernatant following treatment, provided that
S100 fraction, a source of bid, was added. The release
of Smac/DIABLO by GzmB plus S100 was difficult to
verify because of the poor specificity of the antibody.
These data show that GzmA initiates a pathway of mito-
chondrial disruption that is distinct from that caused by
caspase activation. Generation of ROS and loss of ψ
occur in response to GzmA in the absence of added
cytosolic factors and without apparent dissolution of
the MOM.
Granzyme A Induces ROS Accumulation in Target
Cells upon CTL Attack
To test whether GzmA release by cytotoxic T cells re-
sults in ROS production in target cells, we used HE
staining and confocal fluorescence microscopy to de-
tect ROS in primary T cell:target cell conjugates. P14
mice expressing a transgenic T cell receptor that rec-
ognizes the LCMV antigen gp33 in the context of class
I major histocompatibility complex (Pircher et al., 1989)
































mFigure 2. CTL Attack Induces ROS Production in EL4 Target Cells
bEL4 target cells, pulsed with irrelevant control peptide (gag) or with
the specific LCMV gp33 peptide, were stained with the cell marker i
dye CellTrace Far Red DDAO-SE. GzmB−/− P14 CTL cells were d
stained with FITC-conjugated anti-CD3. All cells were further d
stained for ROS with HE just before analysis by confocal micro-
pscopy. The top panels show cells from slides with either target cells
dor CTLs alone. In the bottom panels, the target and effector cells
were separately stained and then allowed to form conjugates for
30 min in Ca2+-free buffer before incubation in Ca2+-free (plus l
EGTA) or Ca2+-containing buffer for 1 min, staining with HE, and i
confocal microscopy analysis. CTLs trigger ROS production in c
target cells bearing gp33 specific peptide, but not the nonspecific
Dgag peptide, only in the presence of extracellular Ca2+, which is
Crequired for granule release. These data are representative images
ofrom one of four independent experiments.
s
t
det al., 1996) . CD8+ CTLs derived from P14xGzmB−/− mice
mwere used as effector cells against EL4 target cells pre-
cpulsed with either specific gp33 peptide or a control
cirrelevant HIV gag peptide. Before the cells were mixed,
iCTLs were stained with antibody to CD3, and EL4 cells
were labeled with CellTrace Far Red dye (DDAO-SE)
(Figure 2). The effector and target cells were incubated G
Atogether for 30 min in calcium-free medium to allow
conjugates to form, and cell death by granule exo- T
acytosis was then triggered synchronously by adding
Ca2+. Within 1 min of adding Ca2+, there was a dramatic W
Gincrease in ROS production in gp33 peptide-loaded
EL4 cells that was not seen in control peptide-loaded t
ocells. ROS staining 5 min after initiating granule exo-
cytosis was indistinguishable from that seen after 1 min l
d(data not shown). If granule exocytosis was preventedy chelating Ca2+ with EGTA, there was no increase in
OS production, even in the presence of specific pep-
ide. As the GzmB cluster knockout mice efficiently ex-
ress only GzmA, these data strongly suggest that
FN-mediated delivery of GzmA by CTL granule exo-
ytosis induces rapid ROS production in the target cell.
oreover, both murine and human GzmA trigger rapid
OS production in target cells.
zmA-Induced ROS Accumulation and  Loss Are
nsensitive to bcl-2 Overexpression and Occur
ndependently of Caspase Activation
zmA-activated cell death is caspase independent,
nd our results in Figure 1 suggest that mitochondrial
amage also occurs by a different pathway than that
nduced by caspase activation. Overexpression of bcl-2
nhibits caspase-dependent mitochondrial damage. To
est the role of the bcl-2/caspase pathway in GzmA-
nduced mitochondrial disruption, we examined ROS
roduction and mitochondrial ψ in Jurkat cells trans-
ected to overexpress bcl-2 (Figure 3A). GzmA loading
aused a dose-dependent increase in intracellular ROS
n bcl-2-overexpressing Jurkat cells that was indistin-
uishable from the increase seen in control cells trans-
ected with the empty vector (Figure 3B). As expected,
OS production in Jurkat and Jurkat-bcl-2 cells re-
uired treatment with both GzmA and PFN. In addition,
he disruption of ψ seen after the addition of GzmA
lus PFN was also insensitive to bcl-2 overexpression
Figure 3C). Together, these results demonstrate that
elivery of GzmA by PFN into Jurkat cells disrupts
itochondrial function via a pathway that cannot be
locked by bcl-2 overexpression. Unlike for GzmA-
nduced mitochondrial damage, bcl-2 overexpression
ampens GzmB- or staurosporine-induced mitochondrial
amage (Figures 3B and 3C), confirming that overex-
ressing bcl-2 inhibits caspase-dependent mitochon-
rial damage.
To probe further whether the observed ROS accumu-
ation and loss of ψ in Jurkat cells treated with GzmA
s caspase dependent, we treated cells with the pan-
aspase inhibitor zVAD-fmk and the caspase-3 inhibitor
EVD-fmk before exposing the cells to GzmA and PFN.
aspase inhibition did not decrease the accumulation
f ROS (Figure 3D) or the loss of ψ (Figure 3E) in re-
ponse to GzmA and PFN. The caspase inhibitors par-
ially blocked the loss of ψ induced by UV treatment,
emonstrating that caspase-dependent pathways of
itochondrial damage were in fact inhibited at the indi-
ated doses of zVAD-fmk and DEVD-fmk. These data
onfirm that mitochondrial damage induced by GzmA
s caspase independent.
zmA-Induced ROS Accumulation and Loss of 
re Attenuated by Inhibiting the Permeability
ransition Pore and by Antioxidants
nd Free Radical Scavengers
e next assessed whether the mitochondrial effects of
zmA involve opening the mitochondrial permeability
ransition (PT) pore. When the mitochondrial PT pore
pens, the mitochondrial inner membrane potential col-
apses as a consequence of dissipating the proton gra-
ient generated in the mitochondrial intermembrane
Granzyme A-Induced Mitochondrial Damage
359Figure 3. GzmA-Induced ROS and Loss of ψ Is bcl-2 Insensitive and Caspase Independent
(A) bcl-2 expression is greatly increased in Jurkat cells stably transfected to express bcl-2. Whole-cell lysates from Jurkat-neo cells trans-
fected with the empty vector and Jurkat-bcl-2 cells were analyzed by immunoblot for bcl-2 and β-actin expression.
(B) GzmA-induced increase in ROS measured by HE staining is not attenuated in Jurkat-bcl-2 cells. Cells were treated as indicated for 1 hr
at 37°C before HE staining. bcl-2 overexpression inhibits ROS generation by GzmB.
(C) GzmA-induced loss of ψ, detected by JC-1 staining, is not affected by bcl-2 overexpression.
(D and E) ROS generation and loss of ψ in K562 cells after treatment with GzmA and PFN is not altered by 100 M zVAD-fmk and 100 M
DEVD-fmk (bottom row). As expected, these caspase inhibitors interfered with UV-induced mitochondrial damage. These data are representa-
tive of three independent experiments.
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360space. Opening the PT pore uncouples the respiratory g
mchain and leads to overproduction of superoxide ani-
ons (Kroemer et al., 1998; Zamzami et al., 1996). To de- e
stermine the contribution of PT pore function on GzmA-
induced ROS accumulation and loss of ψ, cells were l
ploaded with GzmA in the presence of two inhibitors of
the PT pore, cyclosporine A (CsA) and bongkrekic acid s
D(BA), and ROS production and ψ were measured. Both
CsA and BA reduced the accumulation of ROS (Figure f
p4A). In addition, loss of mitochondrial ψ induced by
GzmA could be significantly reduced upon treatment of c
ctarget cells with CsA or BA (Figure 4B). These results
indicate that PT pore opening helps to stimulate pro-
duction of ROS and loss of ψ by GzmA. T
AWe next investigated whether drugs that react with
oxidative intermediates can reduce GzmA-induced i
TROS. K562 cells were incubated with dilutions of the
superoxide scavengers sodium 4,5 dihydroxybenzene- G
t1,3-disulfonate (Tiron) or sodium 3,5-dibromo-4-nitro-
sobenzene sulfonate (D1417) or with the antioxidant p
fand glutathione precursor N-acetyl cysteine (NAC) be-Figure 4. Mitochondrial Damage by GzmA
Depends on PT Pore Opening and Can Be
Inhibited by Antioxidants
(A and B) The PT pore inhibitors cyclo-
sporine A (CsA) and bongkrekic acid (BA) in-
hibit (A) ROS production and (B) loss of ψ
after GzmA and PFN treatment of K562 cells.
(C) Preincubation of K562 cells with the anti-
oxidants N-acetyl cysteine (NAC), Tiron, and
D1417 inhibits GzmA-induced increase in
ROS. Similar results were obtained with Jur-
kat cells.
Data are means and SDs from three inde-
pendent experiments.inning at maximal nontoxic concentrations, deter-
ined for each drug and cell independently as the high-
st concentration that does not lead to increased
pontaneous cell death. The accumulation of intracellu-
ar ROS after GzmA treatment of cells could be com-
letely reversed by incubating cells with either of the
uperoxide scavengers Tiron or D1417 (Figure 4C).
1417 was more effective than Tiron and required 100-
old lower concentrations for complete inhibition. NAC
retreatment also inhibited ROS accumulation, but not
ompletely. Similar results were obtained with Jurkat
ells (data not shown).
he Superoxide Scavenger Tiron Inhibits ROS
ccumulation Induced by GzmA
n Target Cells during CTL Attack
o test the ability of superoxide scavengers to inhibit
zmA-induced ROS production during CTL attack, EL4
arget cells pulsed with specific or control peptide were
reincubated in the presence or absence of Tiron be-
ore adding CD8+ CTLs from P14xGzmB−/− mice as de-
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361scribed earlier. As previously demonstrated, the target
cells show a rapid dramatic increase in the fluores-
cence of the ROS reporter dye HE (Figure 5A, also see
Figure 2). Of note, ROS also increased in the activated
CTLs exposed to gp33-armed target cells. Although all
conjugates showed increased HE staining in the target
cell, only some conjugates had HE-staining CTLs (i.e.,
see Figure 2). In these cultures, CTLs asynchronously
encounter targets and may be differentially stimulated
by different amounts of specific peptide-MHC complexes
on the cell surface. The differential induction of ROS in
CTLs may reflect a transitory or stimulus-dependent
ROS increase in the CTL. In any event, when EL4 targets
were preincubated with Tiron, they displayed little if any
increase in HE fluorescence, even when the CTL had
formed a functional immunological synapse with the
target cell (Figure 5A). Neither Tiron nor D1417 treat-
ment affected the ability of CTLs to deliver GzmA to
target cells, since CTLs conjugated with peptide-
pulsed EL4 cells in the presence or absence of Tiron or
D1417 displayed similar levels of granule exocytosis,
as measured by an in vitro degranulation assay (Figure
5B). This assay is based on the externalization of theFigure 5. Tiron Inhibits ROS Accumulation in
EL4 Target Cells during CTL Attack
(A) CTL granule release was triggered, in the
absence or presence of the superoxide
scavenger Tiron, by gp33-pulsed EL4 target
cells by adding Ca2+ to CTL:target cell con-
jugates, prepared as in Figure 2. ROS pro-
duction, detected by HE staining, only in re-
sponse to the specific peptide, is not
detected in Tiron-treated cells.
(B) CTL degranulation as measured by exter-
nalization of the lysosomal membrane pro-
tein CD107a is not inhibited by treatment
with Tiron or D1417. CTLs were incubated
with EL4 cells pulsed with the irrelevant gag
peptide (unstimulated) or the specific gp33
peptide antigen (stimulated) for 6 hr at 37°C
in the presence of CD107a-FITC. (D1417 ap-
pears to also inhibit the down-modulation of
CD8 observed following T cell activation.)
(C) ROS scavengers do not block Fas-medi-
ated cell death. Jurkat cells were pretreated
with ROS scavengers or medium and then
exposed to Fas antibody CH11 for 6 hr be-
fore analysis of annexin V and PI staining.
These data are representative of at least four
independent experiments.cytotoxic granule integral membrane protein CD107a
(LAMP-1, also expressed on lysosomes), when the
granule membrane fuses with the plasma membrane
during granule exocytosis (Betts et al., 2003). These
data establish Tiron and D1417 as effective inhibitors
of GzmA-induced ROS accumulation in cells under-
going CTL attack.
In addition to granule-mediated apoptosis via the ac-
tion of Gzms and PFN, CTLs can also induce a Gzm-
independent, slower form of apoptosis by engaging
death receptors, such as Fas, in certain settings, such
as during the resolution of the immune response. To
determine whether treatment of target cells with super-
oxide scavengers also inhibits the Fas pathway, Fas-
expressing Jurkat cells, pretreated with buffer, Tiron, or
D1417 at the maximally tolerated concentration, were
examined by annexin V-PI staining 6 hr after exposure
to the agonistic Fas antibody CH11 (Figure 5C). The
superoxide scavengers did not inhibit Fas-mediated
cell death. Therefore, although treatment of target cells
with superoxide scavengers inhibits GzmA-mediated
death, inhibition is specific since they do not block all
killer cell pathways of apoptosis.
Immunity
362Figure 6. Inhibiting ROS Accumulation Protects Cells from GzmA- and CTL-Induced Cell Death
(A and B) K562 cells treated with (A) antioxidants or (B) PT pore inhibitors were analyzed by annexin V-PI staining for susceptibility to cell
death induced by GzmA and PFN. Superoxide scavengers Tiron and D1417 completely inhibited GzmA-induced cell death, while PT pore
inhibitors provided partial protection; NAC was not protective at the highest tolerated concentration.
Granzyme A-Induced Mitochondrial Damage
363whether superoxide scavengers or inhibitors of the PT pp32, and NM23-H1 were detected mostly in the cyto-
(C) Complete inhibition from GzmA-induced cell death by Tiron and D1417 and partial inhibition by CsA was also demonstrated during CTL
attack by using CTLs from P14xGzmB−/− mice to kill gp33-armed EL4 target cells. Cell killing was assessed by 6 hr 51Cr release assay.
(D) The experiment in (C) was repeated by using CTLs from P14 mice in place of CTLs from P14xGzmB−/− mice. CTLs that expressed both
GzmB and GzmA were similarly inhibited.
(E and F) The same inhibitors blocked cytolysis when tested by using human CTL effector cells against human targets. In (E), CTLs are human
LAK cells against conA-coated K562 cells; in (F), CTLs are A2-restricted CMV-specific CTLs against autologous CMV-peptide-coated B-LCL.
Shown are mean and SD of at least three independent experiments.Superoxide Scavengers Inhibit
GzmA-Induced Cell Death
To determine whether increased ROS production was a
byproduct of GzmA-induced cell death, or if ROS pro-
duction itself was necessary for GzmA to cause cell
death, we investigated the ability of GzmA to kill K562
cells in the presence of superoxide ion scavengers or PT
pore inhibitors. Cells were preincubated with dilutions of
each drug, starting with the highest concentration that
was not toxic for the cells (data not shown), and cell
death was measured 1 hr after adding GzmA and/or
PFN by flow cytometry staining for annexin and PI. NAC
had no protective effect on GzmA-induced cell death.
However, when K562 cells were treated with the super-
oxide scavengers Tiron or D1417, GzmA-induced cell
death was completely inhibited (Figure 6A). Since NAC
primarily inhibits the accumulation of free radicals, a
process downstream of superoxide production (Kroemer
et al., 1998; Zamzami et al., 1996), these data suggest
that superoxide generation is required for inducing cell
death in response to GzmA.
GzmA loading in the presence of the PT pore inhibi-
tors CsA or BA partially inhibited cell death (Figure 6B).
At the doses used for this experiment, CsA and BA sig-
nificantly inhibited both ROS production and ψ loss,
but the inhibition was incomplete (Figures 4A and 4B).
Therefore, inhibition of GzmA-triggered cell death by
different types of inhibitors correlates with the ability of
the inhibitor to block ROS generation and loss of ψ.
There are two possible explanations of the partial inhi-
bition of cell death by PT pore inhibitors. One possi-
bility is that GzmA-induced mitochondrial damage and
cell death proceeds by both PT pore-dependent and PT
pore-independent mechanisms. The other possibility is
that mitochondrial damage requires PT pore opening,
but the inhibitors at the highest tolerated doses only
incompletely block PT pore opening. Similar results
were obtained with Jurkat cells (data not shown).
The results obtained with annexin V-PI staining of
GzmA- and PFN-treated target cells, were tested in the
more physiological setting of CTL lysis. Cell death in-
duced by P14xGzmB−/− splenic T cells against anti-
genic peptide-pulsed EL4 cells was assessed by 51Cr
release assay. As they did for GzmA and PFN treatment,
Tiron and D1417 completely inhibited CTL killing (Fig-
ure 6C). At the same concentration, cells treated with
Tiron or D1417 remained susceptible to Fas-mediated
killing (Figure 5C), demonstrating that all forms of apo-
ptosis may not require ROS generation. As we found
for GzmA and PFN loading, CsA also partially inhibited
CTL killing (Figure 6C).
Because of the effectiveness of these inhibitors at
blocking GzmA-induced death, and the possible thera-
peutic implications of our finding, we next testedpore might also block cell death induced by the other
Gzms. The CTL experiments were therefore also per-
formed with mouse and human CTLs that express all
of the Gzms. Cytotoxicity by mouse CTLs from TCR
transgenic P14 mice tested against cognate peptide-
coated EL4 target cells was also completely inhibited
by the superoxide scavengers Tiron and D1417 and
partially inhibited by CsA (Figure 6D). Human CTL lines
were either lymphokine-activated killer (LAK) cells
tested against concanavalin A (conA)-coated K562
targets (Figure 6E) or A2-restricted CMV peptide-spe-
cific CTLs tested against peptide-coated autologous
B-LCL targets (Figure 6F). The inhibitory effects of CsA,
Tiron, and D1417 on killing by human CTLs were similar
to that obtained with mice cells, with complete inhibi-
tion by superoxide scavengers and partial inhibition by
CsA. However, D1417 was a somewhat less effective
inhibitor in human cells than it was in mouse cells, and
it required about a log higher concentration for com-
plete inhibition. Because superoxide scavengers pro-
tected against cell death induced by CTLs from both
P14xGzmB−/− mice and GzmB+ P14 mice as well as
from death by CTLs stimulated in different ways from
blood lymphocytes from various healthy human do-
nors, we can conclude that superoxide anion genera-
tion is essential for the execution of cell death by
GzmB, as well as GzmA. Because the less abundant
Gzms (such as GzmC and GzmM) may not have been
highly expressed by these CTLs, we cannot be certain
whether superoxide scavengers will also block the ac-
tion of these less well-studied Gzms.
GzmA-Induced ROS Accumulation Triggers
the Translocation of the SET Complex
from the Cytoplasm to the Nucleus
The GzmA-activated DNase (GAAD/NM23-H1) is part of
an ER-associated complex that contains pp32, SET,
HMG2, and Ape1 (Fan et al., 2003a). SET inhibits the
DNase. After GzmA loading with PFN or CTL attack,
SET and NM23-H1 translocate into the nucleus by an
unknown mechanism, and nuclear SET is degraded by
GzmA cleavage, activating NM23-H1 to nick chromo-
somal DNA.
Since we hypothesized that the SET complex is in-
volved in the oxidative stress response, we reasoned
that ROS accumulation in response to GzmA mito-
chondrial damage could trigger the nuclear transloca-
tion of the SET complex. To test this hypothesis, we
first asked whether H2O2 treatment could alter the sub-
cellular localization of the SET complex components
SET, pp32, and NM23-H1 in K562 cells. Cells were
treated with H2O2 and separated into cytosolic and
nuclear fractions, and the SET complex proteins in
each fraction were analyzed by immunoblotting. SET,
Immunity
364Figure 7. Oxidative Stress Triggers Nuclear Translocation of SET Complex Proteins
(A) Oxidative stress induced by adding H2O2 to K562 cells triggers rapid translocation of SET, pp32, and NM23-H1 from the cytoplasm to the
nucleus within 1–2 min. Cell were lysed and fractionated at the indicated times after adding H2O2.
(B) GzmA and PFN treatment of K562 cells induces translocation of SET complex proteins. A progressive decrease in cytosolic and corre-
sponding increase in nuclear SET complex proteins occurs over time.
(C) Tiron inhibits GzmA-induced SET complex protein translocation. Cells were treated with GzmA and PFN in the absence or presence of 80
mM Tiron. Similar results were obtained with Jurkat cells.
(D) Laser scanning confocal fluorescence microscopy confirms the nuclear translocation of the SET complex protein NM23-H1 and its
inhibition by Tiron. HeLa cells, treated for 5–10 min in the absence or the presence of Tiron, were stained for NM23-H1 and histone H1 without
fixation to avoid artifacts due to oxidation during fixation. These data are representative of five independent experiments.
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365pathway is caspase independent, since it is not inhib-NM23-H1 moved into the nucleus by 10 min and
(E) Critical role of mitochondrial damage in GzmA-mediated cell death. GzmA, delivered into the target cell by PFN, activates loss of mito-
chondrial transmembrane potential (ψ) and increased ROS, including superoxide ion (O2−). Superoxide triggers translocation of the ER-
associated SET complex into the nucleus. The superoxide scavengers Tiron and D1417 can prevent this process. GzmA (through an unknown
mechanism) also translocates to the nucleus. In the nucleus, GzmA cleaves SET, releasing the GzmA-activated DNase (NM23-H1) from
inhibition, and also cleaves other SET complex proteins (Ape1 and HMG-2), the lamins, histone H1, and the tails from the core histones.
Histone cleavage by GzmA opens up chromatin for efficient DNA damage by NM23-H1. (This model figure was adapted from a recent review
of the GzmA pathway [Lieberman and Fan, 2003].)sol in untreated K562 cells, whereas, in H2O2-treated
cells, there was a rapid appearance of these proteins
in the nuclear fraction (Figure 7A). Although most of
eachof these proteins remained in the cytosolic frac-
tion, within 1 min of H2O2 treatment, an increase in
nuclear SET, pp32, and NM23-H1 was observed, and
by 2 min, the amount in the nucleus had stabilized. The
translocation appeared to be coordinate, suggesting
that the whole complex translocated together. There
was no trace of the control protein β-actin in the
nuclear fraction, or of histone H1 in the cytoplasmic
fraction, indicating complete separation of the nuclear
and cytoplasmic fractions. These data strongly suggest
that oxidative stress triggers the nuclear translocation
of the SET complex proteins.
In agreement with the idea that accumulation of ROS
may drive the translocation of the SET complex, treat-
ment of K562 cells with GzmA plus PFN caused a rapid
nuclear relocation of the SET complex proteins starting
at 5 min, the earliest time point analyzed (Figure 7B). In
cells treated with GzmA alone or PFN alone, SET, pp32,
and NM23-H1 remained cytosolic. The nuclear accu-
mulation of SET, pp32, and NM23-H1 after GzmA treat-
ment was associated with a decrease of the cyto-
plasmic level of these proteins. The GzmA cleavage
product of SET was only detected in the nucleus of
cells treated with both GzmA and PFN, suggesting that
GzmA cleavage occurs mostly in the nucleus, where
GzmA is known to concentrate (Fan et al., 2003b; Jans
et al., 1998).
To prove that the ROS accumulation induced by GzmA
treatment is responsible for SET complex nuclear translo-
cation, we determined the subcellular localization of
SET complex proteins in the absence or presence of
Tiron (Figure 7C) or D1417 (data not shown). As in Fig-
ure 7B, in untreated K562 cells or cells treated with
GzmA alone or PFN alone, SET, pp32, and NM23-H1
were concentrated in the cytoplasmic fraction, while, in
cells exposed to GzmA plus PFN, the proteins appear in
the nuclear fraction (Figure 7C). When K562 cells were
treated with GzmA plus PFN in the presence of Tiron or
D1417, however, nuclear translocation of SET, pp32,
and NM23-H1 was blocked.
Immunostaining and confocal microscopy also dem-
onstrated the translocation of NM23-H1 in HeLa cells
after treatment with GzmA or H2O2 and its inhibition by
the free radical scavenger Tiron. Untreated HeLa cells
or cells treated with GzmA and/or PFN, or H2O2 in the
presence or absence of Tiron, were stained with anti-
bodies to NM23-H1 and histone H1. NM23-H1 was pri-
marily perinuclear in untreated cells and in cells treated
with GzmA, PFN, or Tiron alone (Figure 7D). In contrast,
in cells treated with GzmA plus PFN or H2O2, much ofstained in a similar pattern as histone H1. Furthermore,
Tiron pretreatment blocked NM23-H1 translocation in-
duced by GzmA and PFN. SET staining under all these
conditions mimicked NM23-H1 staining (data not shown).
Taken together, these results demonstrate that the
increase in intracellular ROS initiated by GzmA is re-
sponsible for the translocation of SET complex pro-
teins, and that superoxide plays a key role in this
process.
Discussion
Mitochondria play an important role in caspase-medi-
ated apoptosis, in which disruption of MOM integrity
releases a number of key intermembrane proteins, such
as cytochrome c, that help activate apoptosis when re-
leased from the mitochondrion, despite the fact that
they contribute to normal metabolic function and cell via-
bility within the mitochondrion. Signs of mitochondrial
metabolic dysfunction—increased ROS and loss of the
membrane potential difference between the inner and
outer membranes—are also hallmarks of apoptotic
mitochondrial damage. However, increased ROS and
loss of ψ, because they signal mitochondrial dysfunc-
tion, are characteristic of necrotic cell death as well.
Although many of the critical molecules involved in
mitochondrial pathways of apoptosis have been iden-
tified, how these different aspects of mitochondrial
damage in caspase-dependent apoptosis fit together,
as well as their relative importance and the molecular
basis for their activity are still incompletely understood
and controversial, despite extensive study (Green and
Kroemer, 2004; Newmeyer and Ferguson-Miller, 2003).
It has never been completely clear whether generation
of ROS is central to apoptosis or merely a side effect
of mitochondrial dysfunction.
In this study, we find that generation of ROS, particu-
larly superoxide ion, is critical for the distinct caspase-
independent cell death pathway triggered by the CTL
and NK cell protease GzmA, which has all the morpho-
logical features of apoptosis (model shown in Figure
7E). The experiments in this study were performed by
using recombinant human GzmA and GzmA-expressing
cytotoxic T cells derived from both mice and humans
assayed against a variety of mouse and human target
cells. Our conclusions, therefore, are broadly applicable
across targets and species. Pretreatment of mouse and
human target cells with superoxide scavengers com-
pletely inhibits GzmA-mediated cell death. GzmA trig-
gers mitochondrial damage with rapid increase in ROS
and loss of ψ, but leaves the outer membrane intact
so that cytochrome c and other apoptotic mediators
do not escape. Moreover, this mitochondrial damage
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366ited by overexpression of bcl-2 or by pan-caspase in- a
Fhibitors. In addition, we have begun to understand why
ROS generation is critical for executing the GzmA v
iapoptotic pathway. ROS triggers the nuclear transloca-
tion of the SET complex, an important target of GzmA. H
mThe SET complex contains the GzmA-activated DNase,
NM23-H1, as well as its inhibitor, SET, which when s
ncleaved by GzmA activates the DNase. Moreover, the
rapid translocation of the SET complex in response to h
poxidative stress and its inhibition by superoxide scav-
engers lends support to our hypothesis that the SET a
icomplex is an oxidative stress response complex.
ROS generation was found to be critical not only for a
athe GzmA pathway, but also for cell death induction via
granule exocytosis by CTLs expressing GzmB in addi- G
tion to GzmA. These findings were demonstrated by
using a variety of CTLs from both humans and mice. e
aSince GzmB activates caspase-dependent apoptosis
(as well as caspase-independent cell death), this sug- c
pgests that ROS generation may also be critical for some
caspase-dependent apoptotic pathways in some cells. s
PPrevious studies have also suggested that blocking
ROS generation can inhibit other forms of apopto- e
ssis, including that induced by death receptor ligation,
cytokine withdrawal, and T lymphocyte activation- n
cinduced cell death (Chang et al., 1992; Hildeman et al.,
1999; Hockenbery et al., 1993; Sandstrom et al., 1994). a
DTaken together, these studies suggest that generation
of ROS is often integral to apoptosis induction, not just l
lan epiphenomenon. Our results suggest that the gran-
ule pathways of killer cell apoptosis require superoxide p
sgeneration, while the death receptor pathways may not.
The molecular basis for caspase-independent mito- a
ochondrial damage by GzmA remains to be worked out.
Mitochondrial damage requires the proteolytic activ-
iity of GzmA, since the catalytically inactive enzyme
S-AGzmA does not induce mitochondrial damage (data t
2not shown). It involves direct action of GzmA on a mito-
chondrial substrate since we could demonstrate in- t
pcreased ROS (Figure 1D) and loss of mitochondrial ψ
(not shown) by incubating isolated mitochondria only p
Swith GzmA. Several studies have suggested that two
other Gzms (B and C) are also able to trigger increased c
WROS and loss of mitochondrial ψ in a caspase-inde-
pendent manner through an unknown mechanism. It is c
dpossible that these proteases all target the same mito-
chondrial protein. t
nOur results have therapeutic implications for clinical
situations in which ebullient granule-mediated cytolytic c
Sactivity by CTLs or NK cells has adverse conse-
quences, such as in posttransplant graft versus host b
cdisease or autoimmunity. ROS scavengers or other an-
tioxidants might be effective in these situations in inhib- c
witing apoptosis induced by granule exocytosis. At some
concentrations, these agents might selectively block s
cthe apoptotic effects of granule exocytosis, but leave
other immune apoptotic pathways unaffected. For ex- a
sample, although granule exocytosis is the major path-
way used by killer immune cells to eliminate viruses i
wand cancer cells, engagement of cell death receptors,
such as Fas, is thought to be important for terminating p
sthe immune response and controlling the survival of ac-
tivated T cells. At the maximally tolerated concentra- a
dtion, superoxide scavengers tested in this study wereble to inhibit granule exocytosis, but had no effect on
as-mediated apoptosis of Jurkat T cells, despite pre-
ious reports of effectiveness of antioxidants at block-
ng Fas-mediated apoptosis (Malassagne et al., 2001).
owever, other work suggests that ROS generation
ay actually protect cells from Fas-mediated apopto-
is (Aronis et al., 2003). We have found that ROS does
ot increase in Fas-treated Jurkat cells until after cells
ave externalized phosphatidyl serine and become
ermeabilized to PI (data not shown), suggesting that
n increase in ROS is a late nonessential phenomenon
n this pathway. However, the maximal concentration of
ntioxidants tolerated by Jurkat cells was not as high
s was used to protect K562 or EL4 target cells from
zmA or CTL attack.
In this study, the superoxide scavengers were most
ffective not only at preventing ROS generation, but
lso at protecting cells from GzmA- and CTL-induced
ell death. The PT pore inhibitors provided only partial
rotection. It is not clear whether this is because only
ome of the ROS generation requires opening of the
T pore or whether the inhibitors are not completely
ffective. NAC was significantly less effective than the
uperoxide scavengers at neutralizing ROS and was
ot able to protect cells from death. This may be be-
ause NAC acts more distally in the oxidative pathway,
llowing some active superoxide to wreak its damage.
amage to the integrity of the plasma membrane is
ikely to be a key component of cell death, and the mo-
ecular basis for disruption of the plasma membrane is
oorly understood. Our results perhaps suggest that
uperoxide damage to plasma membrane lipids may be
n important component that can be blocked by super-
xide scavengers, but not by antioxidants like NAC.
We previously postulated, based on the functions of
ts components, that the SET complex is involved in
he oxidative stress repair response (Fan et al., 2003a,
003b). Our finding here that the SET complex proteins
ranslocate to the nucleus within a minute or two of
eroxide treatment supports this hypothesis. We also
reviously found that the SET complex proteins, Ape1,
ET, and NM23-H1, move into the nucleus of target
ells within 5–20 min of initiating CTL granule release.
e now find that the SET complex proteins move syn-
hronously into the nucleus in response to different oxi-
ative stresses. GzmA induces rapid ROS generation in
argeted cells. Moreover, scavenging superoxide anions
ot only inhibits ROS build-up, but also blocks SET
omplex protein translocation. This suggests that the
ET complex is triggered to translocate to the nucleus
y ROS. The molecular basis for ROS induction of SET
omplex translocation requires further study. The syn-
hronous translocation of SET, pp32, and NM23-H1 (as
ell as Ape1 [data not shown]) into the nucleus in re-
ponse to peroxide and GzmA suggests that the SET
omplex translocates as a complex into the nucleus,
lthough this remains unproven. We also have not
tudied whether the SET complex remains intact once
n the nucleus. Since others have identified smaller,
150 kDa, SET- and pp32-containing nuclear com-
lexes involved in inhibiting histone acetylation and
tabilizing AU-rich mRNAs (Brennan et al., 2000; Seo et
l., 2001), it is possible that the SET complex partially
isassembles in the nucleus. However, it is also pos-
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more than one complex. Isolation of nuclear SET com-
plex(es) after peroxide treatment will provide a way to
examine this question.
The rapidity of SET complex translocation within a
minute or two in response to ROS generation may also
help explain why the subcellular localization of SET
complex proteins as visualized by immunofluorescence
microscopy studies varies in the literature and depends
on the fixation protocol (Beresford et al., 2001; Fan et
al., 2002, 2003a, 2003b). During the time required for
fixation, ROS may be generated, stimulating the SET
complex to migrate to the nucleus. In all of our studies,
we have been careful to require consistent results from
subcellular fractionation and microscopy. In this study,
we developed a specific staining protocol that avoids
fixation to minimize possible artifacts.
Since the SET complex appears to translocate into
the nucleus in response to oxidative stress, and since
most forms of cell death involve ROS generation, we
would expect to see SET complex translocation in-
duced by other forms of apoptosis and necrosis. Pre-
liminary experiments suggest that this is indeed the
case. GzmA cleaves several of the SET complex pro-
teins (Ape1, SET, and HMG-2) and destroys their normal
functions, including base excision repair. At the same
time, GzmA unleashes the endonuclease activity of
NM23-H1, normally kept under control by SET, to dam-
age DNA. If the role of the SET complex is to repair
oxidative DNA damage and induce expression of repair
response genes, then other apoptotic pathways might
also find ways to disable the repair functions of the SET
complex or transform its repair functions into mecha-
nisms for promoting cell death.
Experimental Procedures
Cell Lines, Antibodies, and Reagents
Cells were grown in K10 medium (RPMI1640 supplemented with
10% fetal calf serum, 2 mM glutamine, 2 mM HEPES, 100 units/
ml penicillin, 100 mg/ml streptomycin). Jurkat-bcl-2 and Jurkat-neo
(kind gifts of John Reed [Torigoe et al., 1994]) were grown in the
same medium with 0.4 mg/ml geneticin. CTL lines were generated
from P14 (Pircher et al., 1989) and P14xGzmB−/− (Pham et al., 1996)
mouse splenocytes activated with 1 g/ml specific LCMV peptide
gp33 (KAVYNFATC) for 1 hr, washed, and cultured in medium to
which 25 IU/ml recombinant human IL-2 was added every other
day beginning on day 2. Cell lines were used for experiments after
8–15 days of culture. Mice were backcrossed and maintained under
specific pathogen-free conditions. Human LAK cells was generated
from healthy donor peripheral blood mononuclear cells maintained
in K10 plus 1000 IU/ml IL-2 for up to 10 days. A CMV-specific CTL
line (98% CD3+, 80% CD8+) specific for an A2-restricted CMV epi-
tope (NLVPMLATL, 50% of all cells tetramer+) was generated by
stimulating normal donor PBMC twice with the cognate peptide (5
g/ml; the second time by using autologous B-LCL stimulator cells)
and culturing in medium containing 20 IU/ml IL-2 and 25 ng/ml IL-
15. The following antibodies were used: cytochrome c (mouse
mAb), apoptosis inducing factor (AIF), CD3-FITC, CD8-PE,
CD107a-FITC, and annexin V-FITC (BD PharMingen, San Diego,
CA); HtrA2, NM23-H1, and bcl-2 (Santa Cruz Biotechnology, Santa
Cruz, CA); bid (rat mAb) (R&D Systems); histone H1 (mouse mAb)
(Chemicon International); Fas (CH11, mouse mAb) (Immunotech);
β-actin (mouse mAb) (Sigma-Aldrich, St Louis, MO), and cyto-
chrome c oxidase IV (Molecular Probes, Eugene, OR). Anti-pp32
(RJ1) and rabbit antiserum to SET peptide 3–16 were produced as
described (Beresford et al., 2001). Rabbit antiserum to endonucle-
ase G was a gift of Dr. Xiaodong Wang (University of Texas South-western Medical Center). Bongkrekic acid (BA), Cyclosporine A
(CsA), 4,5-dihydroxyl-1,3-benzene-disulfonic acid (Tiron), 3,5-
dibromo-4-nitrosobenzenesulfonic acid (D1417), N-acetyl cysteine
(NAC), staurosporine, and propidium iodide (PI) were from Sigma-
Aldrich. HE and CellTrace Far Red DDAO-SE, Alexa488-conjugated
donkey anti-mouse, and Alexa594-conjugated donkey anti-rabbit
Igs were from Molecular Probes; caspase inhibitor peptides were
from Calbiochem-Novabiochem, San Diego, CA; and the gag,
gp33, and CMV peptides were synthesized and purified at the Tufts
Peptide facility. GzmA and inactive S-AGzmA were expressed and
purified as previously reported (Beresford et al., 1999). PFN and
GzmB were purified from rat RNK-16 cells, and cells were loaded
with sublytic concentrations of PFN as described (Shi et al., 1992;
Shi et al., 2000).
Gzm and PFN Treatment
Cells were washed three times in HBSS and resuspended (2 × 104
cells in 60 l final volume) in cell buffer (HBSS with 10 mM HEPES
[pH 7.2], 0.4% BSA, 3 mM CaCl2). A sublytic concentration of PFN
(determined for each cell independently) and/or GzmA (1 M or as
indicated) or GzmB (1 M or as indicated) was added, and the cells
were cultured at 37°C for the indicated time. For some experi-
ments, NP40 cell lysates obtained after 1 hr of incubation were
analyzed by immunoblot for bid. For cell death assays, cells were
stained 1 hr after PFN and/or Gzm treatment with annexin V and PI
and were analyzed by flow cytometry as described (Friedman et
al., 2000).
Intracellular ROS Production and Transmembrane Potential Loss
ROS production was monitored by adding 2 M HE just before flow
cytometry analysis to cells treated for 1 hr (or an indicated time) at
37°C. As a positive control, cells were exposed to 1%–5% H2O2.
Changes in mitochondrial ψ were monitored with the potentio-
metric dye JC-1 by using the Mitochondrial Membrane Potential
Detection Kit (BioCarta US). As a positive control, cells were
treated overnight with 0.1 M staurosporine or cultured overnight
following UV irradiation (100 J/cm2 × 5 min). For inhibition experi-
ments, cells were preincubated for 15–30 min with inhibitors at the
concentrations indicated before adding PFN or Gzms. Flow cytom-
etry analyses were performed by using a Becton Dickinson FACS-
Calibur flow cytometer and Cellquest Pro software.
Isolated Mitochondria Assays
Mitochondria and S100 supernatants were freshly prepared from
mouse liver as described (Susin et al., 2000). Mitochondria (0.5 mg/
ml protein) were incubated with or without S100 supernatant (1 mg/
ml) plus Gzms at indicated concentrations in a total volume of 60
l mitochondrial buffer (220 mM sucrose, 68 mM mannitol, 10 mM
KCl, 5 mM KH2PO4, 2 mM MgCl2, 0.5 mM EGTA, 5 mM succinate,
2 mM rotenone, 10 mM HEPES [pH 7.2]) for 30 min at 37°C. Mito-
chondria were stained with 150 M HE for flow cytometry as de-
scribed above. For detecting release of apoptogenic factors, after
centrifugation at 760 × g for 5 min, the mitochondrial pellet and
supernatant fractions were analyzed by immunoblot.
ROS Production by Confocal Microscopy
EL4 target cells (2 × 106) were pulsed with 0.5 g/ml specific LCMV
peptide gp33 (KAVYNFATC) or an irrelevant HIV gag peptide
(SLYNTVATL) for 1 hr at 37°C, and then washed in Ca2+-free HBSS.
The target cells were stained with 10 M CellTrace Far Red DDAO-
SE for 15 min at 37°C, then washed in Ca2+-free HBSS. Simulta-
neously, syngeneic P14xGzmB−/− CD8+ effector cells (5 × 106) were
stained with 10 g/ml FITC-CD3 for 30 min at room temperature
and washed. The effector cells were mixed with the EL4 targets in
a 5:1 ratio in Ca2+-free HBSS, and the conjugates were allowed to
settle onto poly-lysine-coated slides for 30 min at 37°C. The slides
were washed twice and incubated for 1 min with warm HBSS with
2 M HE containing either 10 mM Ca2+ or 10 mM EGTA. After a
rapid wash in HBSS, the slides were mounted and fluorescence




RCTL degranulation was assayed as previously reported (Betts et
al., 2003), with minor modifications. EL4 cells, pulsed with irrelevant A
PHIV gag peptide or the specific LCMV peptide gp33 as described
above, were mixed in a 5:1 target:effector ratio with P14xGzmB−/−
CD8+ effector cells in the presence of 1 g/ml CD107a-FITC, 1 g/ R
ml anti-CD28, and (1 g/ml) anti-CD49d for 6 hr at 37°C. The cells
were washed, fixed with 3.7% paraformaldehyde, and further A
stained with CD8-PE. Flow cytometry analysis for cell surface z
CD107a expression was performed on gated lymphocytes. c
A
o
SET Complex Translocation a
K562 cells were washed three times in HBSS, and 2–4 × 105 cells C
were incubated with either 1% H2O2 or sublytic PFN and/or GzmA B
(1 M) for the indicated time at 37°C in the absence or presence of
G
80 mM Tiron. Washed cells were lysed with 0.5% NP40 lysis buffer
t
containing protease inhibitors. After centrifugation at 3000 rpm for
T
5 min, the supernatant (cytoplasmic fraction) was separated from
3
the pellet (nuclear fraction). The nuclear pellet was further washed
Band resuspended in NP40 lysis buffer containing 1% Triton X-100
Rand briefly sonicated. The fractions were resolved by immunoblot.
c
9
NM23-H1 Translocation by Confocal Microscopy B
HeLa cells (0.4 × 105) grown overnight on cover slides were washed G
with HBSS and then left untreated or treated for 5–10 min at 37°C D
with H2O2, PFN, and/or GzmA in the presence or absence of Tiron 5
as above. After an additional wash, unfixed cells were incubated B
for 30 min at room temperature in 1× permeabilization/wash (P/W) M
buffer (DB Bioscience) containing 10% donkey normal serum and e
then incubated with antibodies in the same buffer for 1 hr at room t
temperature. After three washes in P/W buffer, the cells were incu- 4
bated with 1–2 mg/ml Alexa594-conjugated donkey anti-rabbit Ig
B
and Alexa488-conjugated donkey anti-mouse Ig for 1 hr at room
D
temperature. After further washes, cover slides were mounted, and
i






For mouse experiments, EL4 target cells (2 × 106) were incubated C
iwith 0.5 g/ml LCMV gp33 peptide for 1 hr in the presence of 100
Ci/ml Na251CrO4 at 37°C. After washing, 2 × 103 target cells were f
dpreincubated or not for 15–30 min at 37°C in triplicate microtiter
wells with the indicated inhibitor. Cells were then mixed with indi- D
cated P14 or P14GzmB−/− effector cells at a 50:1 effector:target s
ratio in 100 l K10 medium and incubated at 37°C for 6 hr. For c
human studies, assay was performed as described above, but with A
K562 cells coated with 5 g/ml conA as targets of human LAK cells
D
or with autologous B-LCL pulsed with 5 g/ml CMV peptide as
c
targets of a CMV-specific CTL line. After centrifugation at 760 × g
a
for 5 min, 45 l supernatant was counted on a TopCount (Packard
FInstrument Company). Specific release is defined as ([cpm − spon-
itaneous release]/[total release − spontaneous release]) × 100. In all
ocases, background cytolysis of unpulsed, control targets was <5%.
2Fas-mediated apoptosis was triggered by incubating Jurkat cells
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Note Added in Proof
In agreement with our results, caspase-independent mitochondrial
damage was recently described for CTL generated from GzmB−/−
mice (Pardo et al., 2004). These authors also found that NAC could
inhibit ROS, but not block GzmA-induced cell death.
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